20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Amyris Inc (NASDAQ:AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ:IBRX) to commercialize a next-gen COVID-19 vaccine.
- The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the next month.
- ImmunityBio will be responsible for manufacturing the vaccine once human trials are completed in South Africa.
- Amyris will contribute its RNA technology licensed from the Infectious Disease Research Institute (IDRI).
- Amyris will also provide sustainable squalene, an organic compound used to produce the vaccine.
- Upon completion of human trials, the joint venture's goal is to deliver one billion doses of the new vaccine in 2022.
- Price Action: AMRS shares are down 3.94% at $13.53, and IBRX shares are up 2.14% at $8.62 during the market session on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!